CS
BCAX

Candriam SCA’s Bicara Therapeutics BCAX Stock Holding History

Candriam SCA’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.75M Buy
+238,822
New +$4.11M 0.02% 402

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Candriam SCA's BCAX Position: Q1 2026 in Review

Candriam SCA opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 238,822 shares worth $4.75M. The stake represents 0.02% of the portfolio and ranks #402 among its holdings.

146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Candriam SCA held 238,822 shares of Bicara Therapeutics worth $4.75M as of Q1 2026.
  • Bicara Therapeutics was a new Candriam SCA position in Q1 2026.
  • Bicara Therapeutics made up 0.02% of Candriam SCA's portfolio in Q1 2026, its #402 holding.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.